INCR Intercure

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--

InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City.

This prestigious event will bring together senior management teams from leading cannabis companies including InterCure CEO Alex Rabinovitch, to engage in panel discussions, fireside chats, and one-on-one meetings. For more information about the event please refer to the following link:

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: .

EN
22/05/2024

Underlying

INCRIntercure

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intercure

 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 mil...

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA1of NIS 21 million (Approximately 17% of revenues).Both quarters (Q1 and Q2 of 2024) ended with positive EBITDAs and profit from operations and represents InterCure’s 16th and 17th consecutive quarter of profitability2.Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza. InterCure is entitled to full compensati...

August 29, 2024 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces Expansion of its Strategic partnership with Cookie...

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)-- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies’ branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across Germany, through Cookies Corners. This agreement marks an expansion of InterCure and Cookies’ partn...

August 28, 2024 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cann...

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)-- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City. This prestigious event will bring together senior management teams from leading cannabis companies including InterCure CEO Alex Rabinovitch, to engage in panel discussions, fireside chats, and one-on-one meetings. ...

May 22, 2024 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adj...

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)-- . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2023 Financial Highlights and Milestones Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results. The company's operating pr...

May 1, 2024 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 mill...

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)-- . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. Preliminary full year 2023 Financial Highlights and Milestones Annual revenue for 2023 is estimated at NIS 351 million, and revenue for the H2 2023 is estimated at NIS 140 million. EBITDA for 2023 is estimated at over NIS 50 Million, and H2 2023’s EBITDA is estimated to reach over NIS 20 million and over 14% of revenues. Both Q3&Q4 2023 re...

April 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch